Can a low-dose immune drug help hearts heal after a heart attack?

NCT ID NCT07610538

Recruiting now Knowledge-focused Sponsor: Cambridge University Hospitals NHS Foundation Trust Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study gives low-dose interleukin-2 to people who have had a heart attack and are scheduled for bypass surgery. Researchers want to see how the drug affects certain immune cells (regulatory T cells) inside heart tissue compared to blood. The goal is to understand whether these cells can be boosted to help healing, but this is a small early study focused on measuring changes, not on treatment outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Interleukin-2 (Aldesleukin)
What this could lead to: If successful, this could point toward a way to improve heart healing after a heart attack by boosting protective immune cells.
What could go wrong: This is a very small, early-phase study with only 24 participants. It is designed to measure immune cell changes, not to test whether the drug improves heart function or outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CABG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CABG CORONARY ARTERY DISEASE MYOCARDIAL INFARCTION (MI)

Contacts and locations

Locations

Addenbrooke's Hospital
RECRUITING

Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom
Royal Papworth Hospital NHS Foundation Trust
RECRUITING

Cambridge, Cambridgeshire, CB2 0AY, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.